Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Ann Burtness, Kevin Joseph Harrington, Richard Greil et al. · The Lancet · 2019
Cited by 3,304 works. doi:10.1016/s0140-6736(19)32591-7 Open-access PDF
Authors
- Barbara Ann Burtness
- Kevin Joseph Harrington
- Richard Greil
- Denis Soulières
- Makoto Tahara
- Gilberto de Castro
- Amanda K. Psyrri
- Neus Basté
- Prakash C. Neupane
- Åse Bratland
- Thorsten Fuereder
- Brett G.M. Hughes
- Ricard Mesı́a
- Nuttapong Ngamphaiboon
- Tamara Rordorf
- Wan Zamaniah Wan Ishak
- Ruey‐Long Hong
- René González Mendoza
- Ananya Roy
- Yayan Zhang
References
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- The Efficiency of Cox's Likelihood Function for Censored Data
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology